Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
TUCSON, Ariz., Sept. 06, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11, 2017, at 5:00 p.m. Eastern Time.
A live audio webcast of the presentation can be accessed by visiting the “Investors” section of the Company’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates sample and targeted library preparation for next-generation sequencing, received its first US Patent in 2014. Continuous improvements led to the 2017 launch of its new direct-target sequencing chemistry for DNA analysis. Additional information is available at www.htgmolecular.com.
CONTACT: Ashley Robinson LifeSci Advisors, LLC 617-775-5956 [email protected] TJ Johnson President/CEO HTG Molecular Diagnostics 520-547-2827 x130 [email protected]
